eFFECTOR Therapeutics (EFTR)
OTHER OTC:EFTR
Top Page
No summary available
Positive Factors
Innovative Drug Development
eFFECTOR's focus on STRIs represents a novel approach in cancer treatment, potentially offering unique therapeutic options and competitive advantages in the biotechnology sector.
Negative Factors
Financial Distress
The company's financial instability, characterized by declining revenues and negative equity, raises concerns about its ability to sustain operations and invest in R&D long-term.
Read all positive and negative factors
Positive Factors
Negative Factors
Innovative Drug Development
eFFECTOR's focus on STRIs represents a novel approach in cancer treatment, potentially offering unique therapeutic options and competitive advantages in the biotechnology sector.
Read all positive factors
eFFECTOR Therapeutics (EFTR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$941.00
Dividend YieldN/A
Average Volume (3M)79.17K
Price to Earnings (P/E)―
Beta (1Y)-56.54
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,704,409
10 Day Avg. Volume79,165
30 Day Avg. Volume79,165
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-4.41
Price to Sales (P/S)0.00
P/FCF Ratio-0.86
Enterprise Value/Market Cap6.03K
Enterprise Value/Revenue35.01
Enterprise Value/Gross Profit111.19
Enterprise Value/Ebitda-0.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
eFFECTOR Therapeutics Business Overview & Revenue Model
Company Description
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhib...
How the Company Makes Money
eFFECTOR Therapeutics makes money primarily through the development and potential commercialization of its proprietary drug candidates. The company generates revenue through strategic collaborations and partnerships with larger pharmaceutical comp...
eFFECTOR Therapeutics Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 162.00K | 0.00 | 3.55M | 1.43M | 42.00M | 0.00 |
| Gross Profit | 51.00K | -111.00K | 3.50M | 1.41M | 42.00M | -307.00K |
| EBITDA | -31.84M | -32.78M | -20.36M | 17.59M | 16.05M | -28.05M |
| Net Income | -34.63M | -35.81M | -12.93M | 15.80M | 14.21M | -29.74M |
Balance Sheet | ||||||
| Total Assets | 27.13M | 20.54M | 29.08M | 54.06M | 16.70M | 5.09M |
| Cash, Cash Equivalents and Short-Term Investments | 25.38M | 18.37M | 26.31M | 49.70M | 15.22M | 3.43M |
| Total Debt | 20.25M | 20.55M | 20.28M | 20.03M | 12.96M | 15.24M |
| Total Liabilities | 26.30M | 26.34M | 25.18M | 36.77M | 148.95M | 18.93M |
| Stockholders Equity | 827.00K | -5.79M | 3.90M | 17.28M | 979.00K | -13.84M |
Cash Flow | ||||||
| Free Cash Flow | -29.27M | -29.65M | -26.09M | -24.93M | 13.68M | -27.60M |
| Operating Cash Flow | -29.19M | -29.55M | -25.90M | -24.89M | 13.84M | -27.60M |
| Investing Cash Flow | -864.00K | 14.48M | -17.86M | 565.00K | -154.00K | 84.00K |
| Financing Cash Flow | 35.25M | 21.23M | 2.77M | 58.81M | -1.89M | 20.24M |
eFFECTOR Therapeutics Risk Analysis
eFFECTOR Therapeutics disclosed 87 risk factors in its most recent earnings report. eFFECTOR Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
eFFECTOR Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $941.00 | ― | 617.96% | ― | ― | ― | |
47 Neutral | $9.43M | -0.31 | -97.58% | ― | -46.88% | 34.83% | |
43 Neutral | $3.54M | -0.15 | -381.74% | ― | ― | 98.22% | |
42 Neutral | $3.20M | -0.42 | -157.24% | ― | ― | 25.19% | |
41 Neutral | $4.27M | -0.13 | 212.59% | ― | -41.05% | 57.35% |
* Healthcare Sector Average
EFTR
eFFECTOR Therapeutics
0.02
0.00
0.00%
AIM
AIM ImmunoTech
0.53
-2.47
-82.34%
MTNB
Matinas BioPharma
0.50
-0.08
-13.28%
BOLT
Bolt Biotherapeutics
4.66
-2.74
-37.03%
GRI
GRI Bio
2.40
-39.88
-94.32%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―